Atractylodin attenuates the expression of MUC5AC and extracellular matrix in lipopolysaccharide-induced airway inflammation by inhibiting the NF-κB pathway

Environ Toxicol. 2021 Sep;36(9):1911-1922. doi: 10.1002/tox.23311. Epub 2021 Jun 21.

Abstract

This study aimed to explore the effects of atractylodin (ATR) on lipopolysaccharide (LPS)-induced inflammatory response in human airway epithelial cells. The cytotoxicity was assessed by CCK-8 assay. The mRNA expression and concentration of interleukin (IL)-6, IL-8, and mucin 5AC (MUC5AC) were measured by qRT-PCR and ELISA, respectively. Western blotting was performed to determine protein expression. We found that LPS stimulation increased the mRNA expression and concentrations of IL-6, IL-8, and MUC5AC, as well as the expression of Col-I and FN in 16HBE cells, but this effect of LPS was attenuated by ATR treatment. Mechanistically, ATR suppressed LPS-induced activation of the NF-κB pathway in 16HBE cells. Moreover, ATR repressed ovalbumin-induced airway inflammation and NF-kB pathway in mice. In conclusion, ATR attenuated the expression of MUC5AC and ECM in LPS-induced airway inflammation by inhibiting the NF-κB pathway.

Keywords: NF-κB pathway; atractylodin; extracellular matrix; inflammation; mucus.

MeSH terms

  • Animals
  • Extracellular Matrix
  • Furans
  • Humans
  • Inflammation / chemically induced
  • Lipopolysaccharides / toxicity
  • Mice
  • Mucin 5AC* / genetics
  • Mucus
  • NF-kappa B* / genetics

Substances

  • Furans
  • Lipopolysaccharides
  • MUC5AC protein, human
  • Mucin 5AC
  • NF-kappa B
  • atractylodin